sb 203580 has been researched along with cps 49 in 1 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (cps 49) | Trials (cps 49) | Recent Studies (post-2010) (cps 49) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 9 | 0 | 3 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dennis, PA; Figg, WD; Lepper, ER; Warfel, NA; Zhang, C | 1 |
1 other study(ies) available for sb 203580 and cps 49
| Article | Year |
|---|---|
Importance of the stress kinase p38alpha in mediating the direct cytotoxic effects of the thalidomide analogue, CPS49, in cancer cells and endothelial cells.
Topics: Animals; Butadienes; Cell Death; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Endothelial Cells; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Humans; Imidazoles; Mice; Mice, SCID; Mitogen-Activated Protein Kinase 14; Neoplasms; Nitriles; Pyridines; Structure-Activity Relationship; Thalidomide; Xenograft Model Antitumor Assays | 2006 |